Literature DB >> 29461982

Immune-mediated Pericarditis With Pericardial Tamponade During Nivolumab Therapy.

Daniel V P de Almeida1, Jessica R Gomes1, Fabio J Haddad1,2, Antonio C Buzaid1,3.   

Abstract

A 69-year-old man with metastatic lung adenocarcinoma presented with pericarditis and pericardial tamponade during nivolumab treatment, despite near-complete response on images performed during response evaluation. Further investigation found no evidence of pericardial or pleural cancer involvement, and pathologic evaluation showed immune-related adverse effect. Surgical and steroid treatments were used, with excellent results, and no disease progression on follow-up despite drug discontinuation because of toxicity. Although life-threatening immune-related adverse effects are not frequent when using checkpoint inhibitors, and cardiotoxicity is very rare, different clinical manifestations may occur, and some of them can be fatal in case of inadequate management. It may be challenging to make an etiological diagnosis; however, favorable outcomes can be achieved when prompt directed treatment is promoted.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29461982     DOI: 10.1097/CJI.0000000000000217

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  12 in total

Review 1.  Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.

Authors:  Chandra K Ala; Allan L Klein; Javid J Moslehi
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

2.  Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports.

Authors:  Alessandro Inno; Nicola Maurea; Giulio Metro; Andreina Carbone; Antonio Russo; Stefania Gori
Journal:  Cancer Immunol Immunother       Date:  2021-04-20       Impact factor: 6.968

Review 3.  Cardiovascular toxicities associated with immune checkpoint inhibitors.

Authors:  Jiun-Ruey Hu; Roberta Florido; Evan J Lipson; Jarushka Naidoo; Reza Ardehali; Carlo G Tocchetti; Alexander R Lyon; Robert F Padera; Douglas B Johnson; Javid Moslehi
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

4.  Real-world cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a retrospective controlled cohort study.

Authors:  Chuan Zhang; Zhulu Chen; Chunhua Mo; Diansha Gao; Yuxi Zhu; Shu Qin; Zhong Zuo
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

5.  Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series.

Authors:  Puja Arora; Laura Talamo; Patrick Dillon; Ryan D Gentzler; Trish Millard; Michael Salerno; Craig L Slingluff; Elizabeth M Gaughan
Journal:  Cardiooncology       Date:  2020-09-23

Review 6.  Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors:  Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.606

Review 7.  What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.

Authors:  Marina Frayberg; Anthony Yung; Leyre Zubiri; Daniel A Zlotoff; Kerry L Reynolds
Journal:  Curr Treat Options Oncol       Date:  2021-05-26

Review 8.  Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management.

Authors:  Yu-Wen Zhou; Ya-Juan Zhu; Man-Ni Wang; Yao Xie; Chao-Yue Chen; Tao Zhang; Fan Xia; Zhen-Yu Ding; Ji-Yan Liu
Journal:  Front Pharmacol       Date:  2019-11-29       Impact factor: 5.810

Review 9.  Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors.

Authors:  Flora Pirozzi; Remo Poto; Luisa Aran; Alessandra Cuomo; Maria Rosaria Galdiero; Giuseppe Spadaro; Pasquale Abete; Domenico Bonaduce; Gianni Marone; Carlo Gabriele Tocchetti; Gilda Varricchi; Valentina Mercurio
Journal:  Curr Oncol Rep       Date:  2021-01-07       Impact factor: 5.075

Review 10.  Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review.

Authors:  Grzegorz Sławiński; Anna Wrona; Alicja Dąbrowska-Kugacka; Grzegorz Raczak; Ewa Lewicka
Journal:  Int J Mol Sci       Date:  2020-09-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.